Psilocybin Extracts Could Be the Key to Unlocking Psychedelic Health and Wellness
Psychedelics have made some spectacular breakthroughs to gain legitimacy as mental healthcare products and to become an emerging health and wellness market of its own. As these products enter the regulated consumer market, however, it’s ... [Read]
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for
The market expects ImmunoGen (IMGN) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2020. This widely-known consensus outlook is important in assessing the company’s ... [Read]
An Aging Population is Increasing the Need for Novel Treatments
With the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population has tripled in size over the past 40 ... [Read]
Research and Development Moves the Psychedelics Market Forward
The ongoing surge of development and investment into psychedelic medicine and psychedelic-assisted therapy is the direct result of newfound public support and legitimacy for these revolutionary treatments. That legitimacy is being built on the back ... [Read]
Consumers Continue Flocking to Immune-Boosting Supplements as Health Crisis Rages On
The health crisis has completely changed life as we know it and caused a significant shift in consumer demand for immune-boosting products, vitamins, and supplements. Now, due to growing awareness around heath, the wellness supplements ... [Read]
Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here’s Why
Aptevo Therapeutics Inc. (APVO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ... [Read]
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) Digital 2021
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the ... [Read]
Top ETF of December & Its Best Stocks
ARK Genomic Revolution Multi-Sector ETF ARKG topped the list of the best-performing ETFs of December with impressive returns of about 41%. The rally came amid the pandemic, which has led to a surge in the ... [Read]
Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public ... [Read]
AC Immune Reports Q3 2020 Financial Results and Provides Business Update
Phase 1 trial completed in Lilly Morphomer™ Tau partnership program with plans to evaluate candidates in Alzheimer’s disease and NeuroOrphan indications First-in-class TDP-43 therapeutic and diagnostic programs advance as the target’s role in a newly ... [Read]